Sanofi Pasteur Biologics, LLC

Takeda Pharmaceutical Company Limited

Boston Biopharm Inc.

Sanofi Pastuer Biologies, LLC

Sanofi Pasteur Inc.

Richard L Fahrner

Peter Ciarametaro

C Russell Middaugh

Zahra Shahrokh

Pericles Calias

Jing Pan

Gaozhong Zhu

Teresa Leah Wright

Kris Lowe

James Christian

Russell C Middaugh

The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an iduronate-2-sulfatase (I2S) protein, salt, and a polysorbate surfactant for the treatment of Hunters Syndrome.

Methods and compositions for CNS delivery of iduronate-2-sulfatase

Highly bioavailable compositions and related methods of improving the bioavailability of one or more compounds are disclosed. The compositions and methods disclosed herein may be employed to improve the bioavailability of poorly soluble or poorly bioavailable ingredients (e.g., curcumin) in a subject (e.g., a mammal).

Compositions and methods for increasing the bioavailability of one or more compounds

This invention relates to compositions includingtoxins and/or toxoids and corresponding methods. The compositions of the invention include one or more excipients that increase stability and/or decrease aggregation of the toxins.

Pharmaceutical compositions containingtoxoids A and B

[object Object]

Growing community of inventors

Boxford, MA, United States of America

Richard L Fahrner